Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab

We used Surveillance, Epidemiology, and End Results-Medicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Robert I, Lalla, Deepa, Herbert, Robert J, Doan, Justin F, Brammer, Melissa G, Danese, Mark D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2011
Materias:
Causation and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212922/
https://www.ncbi.nlm.nih.gov/pubmed/21929325
http://dx.doi.org/10.3109/07357907.2011.616251
_version_ 1782216046357250048
author Griffiths, Robert I
Lalla, Deepa
Herbert, Robert J
Doan, Justin F
Brammer, Melissa G
Danese, Mark D
author_facet Griffiths, Robert I
Lalla, Deepa
Herbert, Robert J
Doan, Justin F
Brammer, Melissa G
Danese, Mark D
author_sort Griffiths, Robert I
collection PubMed
description We used Surveillance, Epidemiology, and End Results-Medicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HR] 0.54; 95% Confidence Interval [CI] 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.
format Online
Article
Text
id pubmed-3212922
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Informa Healthcare
record_format MEDLINE/PubMed
spelling pubmed-32129222011-11-15 Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab Griffiths, Robert I Lalla, Deepa Herbert, Robert J Doan, Justin F Brammer, Melissa G Danese, Mark D Cancer Invest Causation and Prevention We used Surveillance, Epidemiology, and End Results-Medicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HR] 0.54; 95% Confidence Interval [CI] 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival. Informa Healthcare 2011-11 2011-09-19 /pmc/articles/PMC3212922/ /pubmed/21929325 http://dx.doi.org/10.3109/07357907.2011.616251 Text en © Informa Healthcare USA, Inc. http://creativecommons.org/licenses/by/2.0/ This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals (http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Causation and Prevention
Griffiths, Robert I
Lalla, Deepa
Herbert, Robert J
Doan, Justin F
Brammer, Melissa G
Danese, Mark D
Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
title Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
title_full Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
title_fullStr Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
title_full_unstemmed Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
title_short Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
title_sort infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab
topic Causation and Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212922/
https://www.ncbi.nlm.nih.gov/pubmed/21929325
http://dx.doi.org/10.3109/07357907.2011.616251
work_keys_str_mv AT griffithsroberti infusedtherapyandsurvivalinolderpatientsdiagnosedwithmetastaticbreastcancerwhoreceivedtrastuzumab
AT lalladeepa infusedtherapyandsurvivalinolderpatientsdiagnosedwithmetastaticbreastcancerwhoreceivedtrastuzumab
AT herbertrobertj infusedtherapyandsurvivalinolderpatientsdiagnosedwithmetastaticbreastcancerwhoreceivedtrastuzumab
AT doanjustinf infusedtherapyandsurvivalinolderpatientsdiagnosedwithmetastaticbreastcancerwhoreceivedtrastuzumab
AT brammermelissag infusedtherapyandsurvivalinolderpatientsdiagnosedwithmetastaticbreastcancerwhoreceivedtrastuzumab
AT danesemarkd infusedtherapyandsurvivalinolderpatientsdiagnosedwithmetastaticbreastcancerwhoreceivedtrastuzumab

Ejemplares similares